EKSO Key Statistics, Chart & Performance
The current stock price of EKSO is 9.53 USD. In the past month the price increased by 122.15%. In the past year, price decreased by -19.48%.
EKSO Latest News, Press Relases and Analysis
EKSO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.61 | 222.19B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.86 | 210.17B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.15 | 144.97B | ||
| SYK | STRYKER CORP | 27.82 | 140.11B | ||
| BDX | BECTON DICKINSON AND CO | 14.24 | 58.61B | ||
| IDXX | IDEXX LABORATORIES INC | 56.05 | 56.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.4 | 49.82B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.9 | 39.51B | ||
| RMD | RESMED INC | 25.17 | 36.37B | ||
| DXCM | DEXCOM INC | 37.58 | 27.26B | ||
| PODD | INSULET CORP | 64.41 | 20.71B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.71 | 18.78B |
Related stock screener links
About EKSO
Company Profile
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Company Info
EKSO BIONICS HOLDINGS INC
101 Glacier Point, Suite A
San Rafael California CALIFORNIA 94804 US
CEO: Jack Peurach
Employees: 61
Phone: 15109841761
EKSO BIONICS HOLDINGS INC / EKSO FAQ
Can you describe the business of EKSO BIONICS HOLDINGS INC?
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
What is the current price of EKSO stock?
The current stock price of EKSO is 9.53 USD. The price increased by 11.46% in the last trading session.
Does EKSO stock pay dividends?
EKSO does not pay a dividend.
What is the ChartMill technical and fundamental rating of EKSO stock?
EKSO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for EKSO BIONICS HOLDINGS INC?
The Revenue of EKSO BIONICS HOLDINGS INC (EKSO) is expected to decline by -17.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for EKSO BIONICS HOLDINGS INC?
EKSO BIONICS HOLDINGS INC (EKSO) currently has 61 employees.
EKSO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EKSO. When comparing the yearly performance of all stocks, EKSO is one of the better performing stocks in the market, outperforming 89.61% of all stocks.
EKSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative.
EKSO Financial Highlights
Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -5.68. The EPS increased by 41.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.21% | ||
| ROE | -110.14% | ||
| Debt/Equity | 0.31 |
EKSO Forecast & Estimates
8 analysts have analysed EKSO and the average price target is 7.91 USD. This implies a price decrease of -17.05% is expected in the next year compared to the current price of 9.53.
For the next year, analysts expect an EPS growth of 59.2% and a revenue growth -17.71% for EKSO